9926 (9926) News
Follow 9926 (9926) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Akeso to Place 20 Million New Shares at HK$97.76 Each
EQUITY | Oct 14, 2026, 01:25 AM UTC
M
Shin Hai Gas reports September revenue of NT$188.4M
Shin Hai Gas Corp. reported September revenue of NT$188.4M versus NT$180.3M in 2025, and Jan–Sep revenue of NT$1,871,149,000 versus NT$1,876,869,000 in 2025. Source: Taiwan Stock Exchange.
EQUITY | Oct 08, 2026, 07:07 AM UTC
L
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up
Summit Therapeutics NASDAQ:SMMT said on Monday that British drugmaker AstraZeneca LSE:AZN would invest $2 billion in the company and collaborate on a series of studies testing their cancer treatments together.Summit's sh
EQUITY | Sep 28, 2026, 10:09 PM UTC
L
US drugmakers turn to China for licensing deals
Merck NYSE:MRK on Monday agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global rights to an experimental cancer drug, making it the latest US drugmaker to license China-developed medicines.
GEOPOLITICS | Sep 28, 2026, 02:31 PM UTC
L
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China
Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced that updated data, including overall survival (OS), from the randomized, double-blind Phase III HARMONi-2 trial featuring the nove
GEOPOLITICS | Sep 13, 2026, 11:00 AM UTC
L
Shin Hai Gas reports Aug revenue NT$179.8M vs NT$178.7M
Shin Hai Gas Corp. posted 2026 Aug revenue of NT$179,837,000 versus NT$178,720,000 in 2025. Jan–Aug 2026 revenue was NT$1,682,714,000 versus NT$1,696,548,000 in 2025.
EQUITY | Sep 09, 2026, 01:37 AM UTC
M
Akeso says ivonescimab met key secondary endpoint in Harmoni-2
Akeso Inc (HKEX:9926) said its ivonescimab met a key secondary endpoint in the Harmoni-2 study.
EQUITY | Sep 03, 2026, 01:31 AM UTC
M
HARMONi-2 study shows OS benefit for ivonescimab monotherapy vs pembrolizumab
Summit Therapeutics said Akeso announced positive overall survival results from the Phase III HARMONi-2 randomized, double-blind study comparing ivonescimab and pembrolizumab monotherapy in PD-L1-positive advanced NSCLC.
GEOPOLITICS | Sep 02, 2026, 09:41 PM UTC
M
Akeso’s ivonescimab hits overall survival secondary endpoint in interim Harmoni-2
Akeso Inc (9926) says interim Phase III Harmoni-2 analysis met overall survival as a key secondary endpoint, showing statistically significant and clinically meaningful benefit versus pembrolizumab in first-line PD-L1-po
EQUITY | Sep 02, 2026, 09:01 PM UTC
L
Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement
Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
EQUITY | Aug 28, 2026, 02:45 AM UTC
M
Akeso 1H loss CNY424.2M vs CNY570.0M
Akeso reported a 1H loss of CNY424.2M versus CNY570.0M.
EQUITY | Aug 27, 2026, 11:04 PM UTC
M
Akeso revenue up 27.92%; net loss narrowed
Akeso reported revenue up 27.92% and net loss narrowed, with results tied to stronger oncology sales and operational gains.
EQUITY | Aug 27, 2026, 02:13 PM UTC